In 2015, a cancer diagnosis involving one of the world’s best-known leaders helped bring a powerful word in medicine into the public conversation: immunotherapy.
Former US president and Nobel Peace Prize laureate Jimmy Carter was 90 when he announced that melanoma had spread to his liver and brain. After surgery, radiation and treatment with pembrolizumab, an immunotherapy drug, scans showed no evidence of the cancer previously identified. His experience became a striking example of how advances in cancer treatment can change the outlook for the once-devastating disease.
Melanoma may be opening another chapter: personalised cancer vaccines.
Melanoma begins in melanocytes, the cells that produce melanin, the pigment that gives skin much of its colour. Most cases develop in the skin, but melanoma can also occur in the eye and, more rarely, other tissues. Though less common than some other skin cancers, it can spread quickly if not detected and treated early.
For Indians, it is important to note that melanoma may not always look like the classic images seen in western health campaigns. In people with darker skin, suspicious lesions can appear on the palms, soles and beneath the nails. Any pigmented spot that changes in size, shape or colour, develops irregular edges, bleeds or fails to heal, deserves medical attention.
On August 19, 2026, Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial of an investigational personalised therapy called intismeran autogene, also known as V940 or mRNA-4157 (vaccine), combined with pembrolizumab.
The trial involved people with high-risk stage IIB to IV cutaneous melanoma, whose tumours had been completely removed. Compared with pembrolizumab alone, the combination kept patients free of recurrence for longer and also delayed the spread of cancer to distant organs. No new or unexpected safety concerns emerged in the initial results. This is the first personalised mRNA based vaccine study, and it showed substantial clinical benefit in patients with melanoma.
The findings are encouraging but they are not the final word. Detailed Phase 3 data—including the size of the benefit, full safety results and whether the treatment improves overall survival—are still awaited. The vaccine remains investigational and is awaiting regulatory review.
What makes the approach remarkable is that the vaccine is made for the individual patient. After surgery, scientists analyse the tumour’s genetic makeup and identify mutations that produce abnormal proteins called neoantigens—essentially molecular fingerprints of that cancer. Thereafter, computer analysis helps select promising targets for a personalised mRNA treatment.
Once injected, the mRNA gives cells temporary instructions to display these cancer markers, training T cells to recognise and attack cancer cells carrying them. It does not alter the patient’s DNA. Pembrolizumab complements this approach by blocking PD-1, an immune “brake” that cancer cells can exploit to weaken the body’s immune response.
The implications extend beyond melanoma. Personalised mRNA therapies are being studied in lung, bladder and kidney cancers, although success in melanoma does not guarantee similar results elsewhere.
For India, however, the biggest question may be access. Personalised treatment requires sophisticated genetic sequencing, bioinformatics, rapid manufacturing and reliable transportation—all of which can be expensive and difficult to provide beyond major centres.
The melanoma vaccine is not yet a cure or a routine treatment. But, it offers a compelling glimpse of where cancer care may be heading—treatments built around the unique genetic fingerprint of an individual’s tumour.
That is personalised medicine at its most ambitious—and potentially a new way of thinking about cancer treatment.
Shyla Jovitha Abraham is a health and wellness writer, based in Cleveland, and Dr Jame Abraham is chairman, department of hematology/medical oncology and professor of medicine at Cleveland Clinic. The views expressed are his own and do not represent the views of Cleveland Clinic.
